Category: All HBOC

LitAlert ~~ GeneLit.com

    • An Update on the General Features of Breast Cancer in Male Patients—A Literature Review.
    • Sinziana Ionescu S, Nicolescu AC, Marincas M, Madge OL, Simion L.
    • Diagnostics (Basel). 2022 Jun 26;12(7):1554. doi: 10.3390/diagnostics12071554.

    • Pilot study of a culturally sensitive intervention to promote genetic counseling for breast cancer risk.
    • Henderson V, Madrigal JM, Kendall LC, Parekh P, Newsome J, Chukwudozie IB, Comer-Hagans L, Coffey V, Grumbach G, Spencer S, Rodgers C, Kaur R, Balay L, Maga T, Ramamonjiarivelo Z, Balthazar C, Winn R, Watson K, Odoms-Young A, Hoskins KF.
    • BMC Health Serv Res. 2022 Jun 25;22(1):826. doi: 10.1186/s12913-022-08193-x.

    Related:

    Identifier: NCT04082117: Uptake of Genetic Counseling Among African American Women. (ClinicalTrials.gov)

    • Breast Cancer with Low Recurrence Score on Oncotype DX©: Interplay Between Early Recurrence, Lobular Histology and BRCA Mutation.
    • Zarbiv Y, Wygoda YB, Grinshpun A, Hamburger T, Sella T, Breuer S, Maimon O, Rottenberg Y, Peretz T, Kadouri L.
    • Oncol Ther. 2022 Jun 25. doi: 10.1007/s40487-022-00202-7. Epub ahead of print.

    • Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model.
    • Peters MLB, Eckel A, Lietz A, Seguin C, Mueller P, Hur C, Pandharipande PV.
    • Pancreatology. 2022 May 31:S1424-3903(22)00170-3. doi: 10.1016/j.pan.2022.05.003. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers.
    • Beinse G, Just PA, Le Frere Belda MA, Laurent-Puig P, Jacques S, Koual M, Garinet S, Leroy K, Delanoy N, Blons H, Gervais C, Durdux C, Chapron C, Goldwasser F, Terris B, Badoual C, Taly V, Bats AS, Borghese B, Alexandre J.
    • Br J Cancer. 2022 June 25. doi: 10.1038/s41416-022-01900-9. Epub ahead of print.

    • Next-generation sequencing based detection in a patient with three synchronous primary tumors.
    • Wu T, Wan J, Xia K, Yang MQ, Feng L, Yin L, Chen C.
    • Front Oncol. 2022 Jun 24;12:910264. doi: 10.3389/fonc.2022.910264.

    • Genetic testing and its clinical application in prostate cancer management: Consensus statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.
    • Chiu PKF, Lee EKC, Chan MTY, Chan WHC, Cheung MH, Lam M, Ma ESK, Poon DMC.
    • Front Oncol. 2022 Jun 24;12:962958. doi: 10.3389/fonc.2022.962958.

    • Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.
    • Hilton J, Gelmon K, Bedard PL, Tu D, Xu H, Tinker AV, Goodwin R, Laurie SA, Jonker D, Hansen AR, Veitch ZW, Renouf DJ, Hagerman L, Lui H, Chen B, Kellar D, Li I, Lee SE, Kono T, Cheng BYC, Yap D, Lai D, Beatty S, Soong J, Pritchard KI, Soria-Bretones I, Chen E, Feilotter H, Rushton M, Seymour L, Aparicio S, Cescon DW.
    • Nat Commun. 2022 Jun 24;13(1):3607. doi: 10.1038/s41467-022-31199-2.

    Related:

    Identifier: NCT02719977: A Phase I Study of CX5461. (ClinicalTrials.gov)

    • Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).
    • Rosenberg JE, Park SH, Kozlov V, Dao TV, Castellano D, Li JR, Mukherjee SD, Howells K, Dry H, Lanasa MC, Stewart R, Bajorin DF.
    • J Clin Oncol. 2022 Jun 23:JCO2200205. doi: 10.1200/JCO.22.00205. Epub ahead of print.

    • Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.
    • Saad F, de Bono J, Barthélémy P, Dorff T, Mehra N, Scagliotti G, Stirling A, Machiels JP, Renard V, Maruzzo M, Higano CS, Gurney H, Healy C, Bhattacharyya H, Arondekar B, Niyazov A, Fizazi K.
    • Eur Urol. 2022 Jun 21:S0302-2838(22)02407-1. doi: 10.1016/j.eururo.2022.05.030. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Comparison of Survival Outcomes According to BRCA1/2 Variant Type in High-grade Serous Ovarian Cancer.
    • Lee J, Kim JM, Lee YH, Chong GO, Lee NY, Lee IH, Park JY, Hong DG.
    • In Vivo. 2022 Jul-Aug;36(4):1903-1910. doi: 10.21873/invivo.12910.

    • A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044/EBLIN).
    • Lee YJ, Seol A, Lee M, Kim JW, Kim HS, Kim K, Suh DH, Kim S, Kim SW, Lee JY.
    • In Vivo. 2022 Jul-Aug;36(4):1949-1958. doi: 10.21873/invivo.12917.

    Related:

    Identifier: NCT03509246: Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients. (ClinicalTrials.gov)

    • Surgical Outcome Measures in a Cohort of Patients at High Risk of Breast Cancer Treated by Bilateral Risk Reducing Mastectomy and Breast Reconstruction.
    • Gandhi A, Duxbury P, Clancy T, Lalloo F, Wisely JA, Kirwan CC, Foden P, Stocking K, Howell A, Evans DG.
    • Plast Reconstr Surg. 2022 Jun 24. doi: 10.1097/PRS.0000000000009383. Epub ahead of print.

    • Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer.
    • Morgan RD, Burghel GJ, Flaum N, Bulman M, Smith P, Clamp AR, Hasan J, Mitchell C, Salih Z, Woodward ER, Lalloo F, Shaw J, Desai S, Crosbie EJ, Edmondson RJ, Schlecht H, Wallace AJ, Jayson GC, Evans DGR.
    • J Clin Pathol. 2022 Jun 23:jclinpath-2022-208369. doi: 10.1136/jcp-2022-208369. Epub ahead of print.

    • Physical Activity in Young BRCA Carriers and Reduced Risk of Breast Cancer.
    • Bucy AM, Valencia CI, Howe CL, Larkin TJ, Conard KD, Anderlik EW, Valdivi SI, Bea JW.
    • Am J Prev Med. 2022 Jun 20:S0749-3797(22)00246-X. doi: 10.1016/j.amepre.2022.04.022. Epub ahead of print.
    • Review

    • Medicaid Expansions: Probing Medicaid's Filling of the Cancer Genetic Testing and Screening Space.
    • Modell SM, Schlager L, Allen CG, Marcus G.
    • Healthcare (Basel). 2022 Jun 8;10(6):1066. doi: 10.3390/healthcare10061066.

    • RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma.
    • Xie F, Ding D, Lin C, Cunningham D, Wright M, Javed AA, Azad N, Lee V, Donehower R, De Jesus-Acosta A, Le DT, Pishvaian M, Shin EJ, Lennon AM, Khashab M, Singh V, Klein AP, Roberts NJ, Hacker-Prietz A, McPhaul T, Burkhart RA, Burns WR, Narang A, Zaheer A, Fishman EK, Thompson ED, Anders R, Yu J, He J, Wolfgang CL, Zheng L, Liu D, Wu K, Laheru DA.
    • JCO Precis Oncol. 2022 Jun;6:e2100404. doi: 10.1200/PO.21.00404.

    • LitAlert ~~ GeneLit.com

    • New Adjuvant Treatment for High-Risk Early Breast Cancer.
    • Aschenbrenner DS.
    • Am J Nurs. 2022 Jul 1;122(7):26. doi: 10.1097/01.NAJ.0000842240.11650.1d.
    • News

    • Tumor immune microenvironment changes by multiplex immunofluorescence staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a hereditary BRCA mutation.
    • Kumar T, Hobbs E, Yang F, Chang JT, Contreras A, Parra Cuentas ER, Garber H, Lee S, Lu Y, Scoggins ME, Adrada BE, Whitman GJ, Arun BK, Mittendorf EA, Litton JK.
    • Clin Cancer Res. 2022 Jun 23:clincanres.1278.2021. doi: 10.1158/1078-0432.CCR-21-1278. Epub ahead of print.

    • Classification of BRCA2 variants of uncertain significance (VUS) using an ACMG/AMP model incorporating a homology directed repair (HDR) functional assay.
    • Hu C, Susswein LR, Roberts ME, Yang H, Marshall ML, Hiraki S, Berkofsky-Fessler W, Gupta S, Shen W, Dunn CA, Huang H, Na J, Domchek SM, Yadav S, Monteiro ANA, Polley EC, Hart SN, Hruska KS, Couch FJ.
    • Clin Cancer Res. 2022 Jun 23:clincanres.0203.2022. doi: 10.1158/1078-0432.CCR-22-0203. Epub ahead of print.

    • Multigene Panel Testing in Turkish Hereditary Cancer Syndrome Patients.
    • Arslan Ates E, Turkyilmaz A, Alavanda C, Yildirim O, Guney AI.
    • Medeni Med J. 2022 Jun 23;37(2):150-158. doi: 10.4274/MMJ.galenos.2022.22556.

    • Programmatic Efforts Increase Adoption of Genomic Precision Medicine in Cancer Care in a Community Cancer Center.
    • Darabi S, Braxton D, Homer J, Brodie T, Holnagel D, Eisenberg B, Demeure MJ.
    • JCO Precis Oncol. 2022 Jun;6:e2200090. doi: 10.1200/PO.22.00090.

    • LitAlert ~~ GeneLit.com

    • Intraductal Papillary Mucinous Neoplasms in Hereditary Cancer Syndromes.
    • Ardeshna DR, Rangwani S, Cao T, Pawlik TM, Stanich PP, Krishna SG.
    • Biomedicines. 2022 Jun 22;10(7):1475. doi: 10.3390/biomedicines10071475.

    • Genomic Breakpoints’ Characterization of a Large CHEK2 Duplication in an Italian Family with Hereditary Breast Cancer.
    • Germani A, Guadagnolo D, Salvati V, Micolonghi C, Mancini R, Mastromoro G, Sadeghi S, Petrucci S, Pizzuti A, Piane M.
    • Diagnostics (Basel). 2022 Jun 22;12(7):1520. doi: 10.3390/diagnostics12071520.

    • What Chris Evert’s Story Can Teach the World about Genetic Testing.
    • Matloff ET.
    • FORCE. Blog. 2022 Jun 22.

    • Psychological and health behaviour outcomes following multi-gene panel testing for hereditary breast and ovarian cancer risk: a mini-review of the literature.
    • Carlsson L, Thain E, Gillies B, Metcalfe K.
    • Hered Cancer Clin Pract. 2022 Jun 22;20(1):25. doi: 10.1186/s13053-022-00229-x.

    • BRCA1, BRCA2, TP53, PIK3CA, PTEN and AKT1 genes mutations in Burkina Faso breast cancer patients: prevalence, spectrum and novel variant.
    • Ouedraogo SY, Zoure AA, Zeye MMJ, Kiendrebeogo TI, Zhou X, Sawadogo AY, Simpore J, Chen H.
    • Mol Genet Genomics. 2022 Jun 22. doi: 10.1007/s00438-022-01914-1. Epub ahead of print.

    • Understanding and predicting the functional consequences of missense mutations in BRCA1 and BRCA2.
    • Aljarf R, Shen M, Pires DEV, Ascher DB.
    • Sci Rep. 2022 Jun 21;12(1):10458. doi: 10.1038/s41598-022-13508-3.

    • LitAlert ~~ GeneLit.com

    • A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report.
    • Iwasawa T, Kosaka T, Morita S, Mikami S, Nakamura K, Hongo H, Nishihara H, Oya M.
    • BMC Med Genomics. 2022 Jun 20;15(1):138. doi: 10.1186/s12920-022-01286-w.

    • Germline landscape of BRCAs by 7-site collaborations as a BRCA consortium in Turkey.
    • Bisgin A, Sag SO, Dogan ME, Yildirim MS, Gumus AA, Akkus N, Balasar O, Durmaz CD, Ersoz R, Altiner S, Alemdar A, Aliyeva L, Boga I, Cam FS, Dogan B, Esbah O, Hanta A, Mujde C, Ornek C, Ozer S, Rencuzogullari C, Sonmezler O, Bozdogan ST, Dundar M, Temel SG.
    • Breast. 2022 Jun 20:S0960-9776(22)00113-8. doi: 10.1016/j.breast.2022.06.005. Epub ahead of print.

    • What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib.
    • Loehr A, Petrylak D, Watkins SP.
    • Front Oncol. 2022 Jun 20;12:951348. doi: 10.3389/fonc.2022.951348.

    • A systematic literature review of the management, oncological outcomes and psychosocial implications of male breast cancer.
    • Rutherford CL, Goodman D, Lannigan A.
    • Eur J Surg Oncol. 2022 Jun 10:S0748-7983(22)00488-7. doi: 10.1016/j.ejso.2022.06.004. Epub ahead of print.
    • Review

    • LitAlert ~~ GeneLit.com

    • Hereditary Breast Cancer in the Brazilian State of Ceará (The CHANCE Cohort): Higher-than-expected prevalence of recurrent germline pathogenic variants.
    • Gifoni ACL, Palmero EI, Wotroba CM, Gifoni MA, Achatz MI, dos Santos W.
    • Front Oncol. 2022 Jun 20;12:932957. doi: 10.3389/fonc.2022.932957.

    • Cost-effectiveness of BRCA 1/2 genetic test and preventive strategies using real-world data from an upper-middle income country.
    • Lourenção M, Correa Galendi JS, HD, Antoniazzi AP, Grasel R, Carvalho AL, Mauad EC, Oliveira JH, Reis RM, Mandrik O, Palmero EI.
    • Front Oncol. 2022 Jun 20;12:951310. doi: 10.3389/fonc.2022.951310.

    • Stress, Anxiety, and Health-Related Quality of Life in BRCA1/2-Positive Women with and without Cancer: A Comparison of Four US Female Samples.
    • Dibble KE, Donorfio LKM, Britner PA, Bellizzi KM.
    • Gynecol Oncol Rep. 2022 Jun 20;101033. doi: 10.1016/j.gore.2022.101033.

    • Chemotherapy Regimens Received by Women with BRCA1/2 Pathogenic Variants for Early-Stage Breast Cancer Treatment.
    • Kurian AW, Abrahamse P, Hamilton AS, Caswell-Jin JL, Gomez SL, Hofer TJ, Ward KC, Katz SJ.
    • JNCI Cancer Spectr. 2022 Jun 20:pkac045. doi: 10.1093/jncics/pkac045. Epub ahead of print.

    • Mutations in exon 11 (11.1 and 11.2) of the BRCA1 gene and risk factors for breast cancer in Burkina Faso.
    • Kiendrebeogo IT, Zoure AA, Zongo FI, Ouattara AK, Ouedraogo MNL, Amegnona J, Yonli AT, Bayala B, Zongo N, Bambara AH, Sawadogo AY, Zohoncon TM, Obiri-Yeboah D, Simpore J.
    • J Public Health Afr. 2022 May 25;13(1):1921. doi: 10.4081/jphia.2022.1921.

    • Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer.
    • Xiao Y, Gao W.
    • Oncol Lett. 2022 May 19;24(1):219. doi: 10.3892/ol.2022.13340.

    • LitAlert ~~ GeneLit.com

    • Environmental Contaminants Modulate Breast Cancer Development and Outcome in TP53 p.R337H Carriers and Noncarriers.
    • Gerber VKQ, Paraizo MM, Ibañez HC, Casali-da-Rocha JC, Pinto EM, Andrade DP, Ibañez MVC, Komechen H, Figueiredo MMO, Custódio G, Fiori CMCM, Balbinotti JHG, Nardin JM, Almeida TA, Beltrame OO, Yamada PA, de Fraga GS, de Brito LL, Martins J, Melanda VS, Licht OAB, Teixeira VZ, Pinho SKS, Bottini S, Lalli E, Zambetti GP, Figueiredo BC.
    • Cancers (Basel). 2022 Jun 19;14(12):3014. doi: 10.3390/cancers14123014.

    • Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations.
    • McGuire KP, Arthur DW, Mamounas EP.
    • Ann Surg Oncol. 2022 Jun 18. doi: 10.1245/s10434-022-12048-4. Epub ahead of print.

    Related:

    Guideline:

    Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.

    Summary, Review:

    Management of Hereditary Breast Cancer: ASCO, ASTRO, and SSO Guideline.

    Guideline:

    Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.

    • Rare germline deleterious variants increase susceptibility for lung cancer.
    • Sang J, Zhang T, Kim J, Li M, Pesatori AC, Consonni D, Song L, Liu J, Zhao W, Hoang PH, Campbell DS, Feng J, D'Arcy ME, Synnott N, Chen Y, Wu Z, Zhu B, Yang XR, Brown KM, Choi J, Shi J, Landi MT.
    • Hum Mol Genet. 2022 Jun 18:ddac123. doi: 10.1093/hmg/ddac123. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
    • Graffeo R, Rana HQ, Conforti F, Bonanni B, Cardoso MJ, Paluch-Shimon S, Pagani O, Goldhirsch A, Partridge AH, Lambertini M, Garber JE.
    • Breast. 2022 Jun 18:S0960-9776(22)00104-7. doi: 10.1016/j.breast.2022.06.003. Epub ahead of print.

    • Prevalence of Pathogenic Germline BRCA1/2 Variants and Their Association with Clinical Characteristics in Patients with Epithelial Ovarian Cancer in a Rural Area of Japan.
    • Abe A, Imoto I, Tange S, Nishimura M, Iwasa T.
    • Genes (Basel). 2022 Jul 18;13(6):1085. doi: 10.3390/genes13061085.

    • Minigene-based splicing analysis and ACMG/AMP-based tentative classification of 56 ATM variants.
    • Bueno-Martínez E, Sanoguera-Miralles L, Valenzuela-Palomo A, Esteban-Sánchez A, Lorca V, Llinares-Burguet I, Allen J, García-Álvarez A, Pérez-Segura P, Durán M, Easton DF, Devilee P, Vreeswijk MPG, de la Hoya M, Velasco-Sampedro EA.
    • J Pathol. 2022 Jun 18. doi: 10.1002/path.5979. Epub ahead of print.

    • Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness.
    • Darbeheshti F, Kadkhoda S, Keshavarz-Fathi M, Razi S, Bahramy A, Mansoori Y, Rezaei N.
    • BMC Cancer. 2022 Jun 17;22(1):668. doi: 10.1186/s12885-022-09761-4.

    • Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.
    • Ratz L, Brambillasca C, Bartke L, Huetzen MA, Goergens J, Leidecker O, Jachimowicz RD, van de Ven M, Proost N, Siteur B, de Korte-Grimmerink R, Bouwman P, Pulver EM, de Bruijn R, Isensee J, Hucho T, Pandey G, van Lohuizen M, Mallmann P, Reinhardt HC, Jonkers J, Puppe J.
    • Breast Cancer Res. 2022 Jun 17;24(1):41. doi: 10.1186/s13058-022-01534-y.

    • Talking about Risk, UncertaintieS of Testing IN Genetics (TRUSTING): development and evaluation of an educational programme for healthcare professionals about BRCA1 & BRCA2 testing.
    • Fallowfield L, Solis-Trapala I, Starkings R, May S, Matthews L, Eccles D, Evans DG, Turnbull C, Crawford G, Jenkins V.
    • Br J Cancer. 2022 Jun 17. doi: 10.1038/s41416-022-01871-x. Epub ahead of print.

    • Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial).
    • Marth C, Abreu MH, Andersen KK, Aro KM, de Lurdes Batarda M, Boll D, Ekmann-Gade AW, Haltia UM, Hansen J, Haug AJ, Høgdall C, Korach J, Lassus H, Lindemann K, Van Nieuwenhuysen E, Ottevanger PB, Polterauer S, Schnack TH.
    • Cancer. 2022 Jun 17. doi: 10.1002/cncr.34350. Epub ahead of print.

    • Optimizing Treatment Selection and Sequencing Decisions for First-Line Maintenance Therapy of Newly Diagnosed Advanced Ovarian Cancer– International considerations amongst upper middle- and high-income countries (UMIC and HIC).
    • Goh JCH, Mclaren Gourley C, Tan DSP, Nogueira-Rodrigues A, Elghazaly H, Pierre M, Giornelli G, Kim BG, Morales-Vasquez F, Tyulyandina A.
    • Gynecol Oncol Rep. 2022 Jun 17;101028. doi: 10.1016/j.gore.2022.101028.

    • The tumor mutational landscape of BRCA2-deficient primary and metastatic prostate cancer.
    • Kensler KH, Baichoo S, Pathania S, Rebbeck TR.
    • NPJ Precis Oncol. 2022 Jun 17;6(1):39. doi: 10.1038/s41698-022-00284-6.

    • Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions: Practical Implications for Pathologists for Tumor Typing and Reporting.
    • Rabban JT, Chen LM, Devine WP.
    • Surg Pathol Clin. 2022 Jun;15(2):219-234. doi: 10.1016/j.path.2022.02.003. Epub 2022 May 18.
    • Review

    • LitAlert ~~ GeneLit.com

    • Surveillance mammography after treatment for male breast cancer.
    • Yadav S, Sangaralingham L, Payne SR, Giridhar KV, Hieken TJ, Boughey JC, Mutter RW, Hawse JR, Jimenez RE, Freedman RA, Khanani S, Couch FJ, Vachon C, Shah N, Leon-Ferre RA, Ruddy KJ.
    • Breast Cancer Res Treat. 2022 Jun 17. doi: 10.1007/s10549-022-06645-w. Epub ahead of print.

    • A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers.
    • Tinker AV, Altman AD, Bernardini MQ, Ghatage P, Gien LT, Provencher D, Salvador S, Doucette S, Oza AM.
    • Curr Oncol. 2022 Jun 17;29(6):4354-4369. doi: 10.3390/curroncol29060348.

    • Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake.
    • Ramsey ML, Tomlinson J, Pearlman R, Abushahin L, Aeilts A, Chen HZ, Chen Y, Compton A, Elkhatib R, Geiger L, Hays J, Jeter J, Jin N, Malalur P, Roychowdhury S, Ruple J, Prebish J, Stanich PP, Hampel H.
    • Fam Cancer. 2022 Jun 17. doi: 10.1007/s10689-022-00300-5. Epub ahead of print.

    • ASO Author Reflections: Sentinel Lymph Node Biopsy in BRCA1/2 Germline Pathogenic Variant Carriers Undergoing Risk-Reducing Mastectomy.
    • Ferroum A, Wong SM.
    • Ann Surg Oncol. 2022 Jun 16. doi: 10.1245/s10434-022-12013-1. Epub ahead of print.
    • Commentary

    • Impact of germline mutations in cancer-predisposing genes on long-term survival in patients with epithelial ovarian cancer.
    • Kotsopoulos J, Zamani N, Rosen B, McLaughlin JR, Risch HA, Kim SJ, Sun P, Akbari MR, Narod SA.
    • Br J Cancer. 2022 Jun 16. doi: 10.1038/s41416-022-01840-4. Epub ahead of print.

    • Validation of the Knowledge of Genome Sequencing (KOGS) scale in cancer patients.
    • Butow P, Napier C, Campbell R, Bartley N, Best M, Ballinger ML.
    • Patient Educ Couns. 2022 Jun 16:S0738-3991(22)00287-7. doi: 10.1016/j.pec.2022.06.009. Epub ahead of print.

    • Nine Myths About Men and Hereditary Cancer.
    • [No author given]
    • My Gene Counsel. Genetic Journal blog. 2022 Jun 15.

    • The Pathogenic R3052W BRCA2 Variant Disrupts Homology-Directed Repair by Failing to Localize to the Nucleus.
    • Jimenez-Sainz J, Krysztofiak A, Garbarino J, Rogers F, Jensen RB.
    • Front Genet. 2022 May 30;13:884210. doi: 10.3389/fgene.2022.884210.